Aerie Pharmaceuticals — Investor Presentation (January 2020)
25 slides from Aerie Pharmaceuticals's investor presentation, Jan 13, 2020

Slide 1: Company Overview Investor Presentation January 2020
Company Overview Investor Presentation January 2020 Exhibit 99.1

Slide 2: Important Information
For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

Slide 3: Aerie Overview
Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. AR-13503 and AR-1105 are development stage product candidates and are no

Slide 4: Glaucoma Market Perspective
For Investor Use Glaucoma Market Perspective - ~$3B Market, 35M TRx, 52M bottles - Half of volume first-line (PGAs) - Half of volume 2-3X/Day Adjuncts 2018 U.S. Glaucoma Market Graph Source: IQVIA 2018 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Source: IMS/NPA Data R12M May

Slide 5: Rhopressa and Rocklatan Positioning
For Investor Use Rhopressa® and Rocklatan® Positioning HCPs positioning as concomitant therapy HCPs positioning as therapy for patients requiring maximal IOP lowering with one drop per day Rhopressa® Positioning Rocklatan® Positioning QD PM dose Lack of serious and systemic AEs QD PM dose Lack of se

Slide 6: Rocklatan Phase 3 Month 12 Responder Analysis
For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

Slide 7: Topline Results from Rhopressa Multi-center Open-label Study (MOST)
Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

Slide 8: U.S. Glaucoma Franchise Launch Update
8 For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 1/10/20 IQVIA Weekly Data as of 1/3/20 1/4/2019 1/10/2020 1/4/2019 1/3/2020 13,321 18,704 6,985 9

Slide 9: Market Access as of January 2020
For Investor Use Market Access as of January 2020 Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage. Rhopressa® Commercial ~ 90% of covered lives Medicare Part D ~ 75% of covered lives Rocklatan® Commercial ~ 80% of covered lives Medicare Part D ~

Slide 10: Active Engagement at Key Conferences
For Investor Use Active Engagement at Key Conferences March 2019: American Glaucoma Society (AGS) April/May 2019: Association of Research in Vision and Ophthalmology (ARVO) May 2019: American Society of Cataract and Refractive Surgeons (ASCRS) July 2019: American Society for Retina Specialists (ASRS

Slide 11: Expanding Aerie Franchise: Europe
For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i

Slide 12: Expanding Aerie Franchise: Japan
For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful top-line results released in November 2019 Phase 3 trials expected to be conducted in Japan Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2019. *TRx calculated from IQVIA unit data (1 month = 1 TRx) Aer

Slide 13: AR-13324-CS208 Japan Phase 2 Study Topline Results
AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

Slide 14: Advancing the Pipeline
For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

Slide 15: U.S. Dry Eye Market
For Investor Use U.S. Dry Eye Market Estimated 30 million dry eye sufferers in the United States Less than 3 million treated Sources: Mixture of public information, IQVIA , Market Scope and estimates US 2018E Sales: $1.54B +12% 5-Yr CAGR

Slide 16: AVX-012 for Dry Eye
For Investor Use AVX-012 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors TRPM8 receptor is a cold thermoreceptor involved in basal tear production (i.e.; sign) Modulation of TRPM8 also provides a cooling sensation upon instillation (i.e.; symptom) This mechanism of acti

Slide 17: AVX-012 (TRPM8 Agonist) for Dry Eye
AVX-012 (TRPM8 Agonist) for Dry Eye For Investor Use

Slide 18: AVX-012 Dry Eye Clinical Trial Highlights
AVX-012 Dry Eye Clinical Trial Highlights Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 over 28 days Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Symptoms: SANDE Score Percentage of patients improving ≥20 score For Investor Use ++Dat

Slide 19: Bringing Small Molecule Therapy to Back of the Eye
Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small molecules address a wider array of therapeutic

Slide 20: Aerie's Ophthalmic Implant Platform
For Investor Use Aerie’s Ophthalmic Implant Platform Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug candi

Slide 21: 2018 U.S. Retinal Disease Market
For Investor Use 2018 U.S. Retinal Disease Market 2018 Sales: $6.0B 2018 Unit Sales: 7.3MM Sources: Mixture of public information, IQVIA, Market-Scope and estimates – March 2019

Slide 22: Aerie's Sustained Implant Opportunities
For Investor Use Aerie’s Sustained Implant Opportunities Markets in Need of Further Innovation: Retinal Vein Occlusion (RVO) Wet Age Related Macular Edema (wAMD) Diabetic Macular Edema (DME) Broadly Underserved Market Opportunities: Glaucoma Neuro-enhancement Dry AMD/Geographic Atrophy (GA)

Slide 23: Aerie's Lead Implant Product Candidates
For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout ~ H2 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administr

Slide 24: Aerie's Key Catalysts for 2020
Aerie’s Key Catalysts for 2020 Pipeline: Avizorex TRPM8 agonist for Dry Eye Phase 2/3 clinical study expected to commence H2 2020 AR-1105 Phase 2 RVO clinical study readout expected H2 2020 AR-13503 clinical study for Neuro-enhancement expected to commence H2 2020 Globalization: Roclanda® Mercury 3

Slide 25: Summary
For Investor Use Summary Key Priorities Successful commercialization in U.S. of Rhopressa® and Rocklatan® Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility – expected to be online H1 2020 Research Initiatives Avizorex TRPM8 agonist for dr
Source: SEC EDGAR · 8-K filed Jan 13, 2020
More decks from Aerie Pharmaceuticals Inc.
Investor Presentation (September 2022)30 slides · Sep 13, 2022
Merger or Acquisition (August 2022)30 slides · Aug 23, 2022
Investor Presentation (June 2022)30 slides · Jun 8, 2022
Investor Presentation (May 2022)28 slides · May 25, 2022
Investor Presentation (April 2022)25 slides · Apr 11, 2022
Investor Presentation (January 2022)33 slides · Jan 5, 2022